Bariatric Surgery vs Glucagon-Like Peptide-1 Analogues for Reducing Risk of Major Cardiovascular Events: A Multi-Center Retrospective Cohort Study

被引：0
|
作者：
Adekolu, Ayowumi A. [1 ]
Cohen, Ethan M. [1 ]
Maan, Soban A. [1 ]
Foryoung, Joyce [1 ]
Thakkar, Shyam A. [1 ]
Singh, Shailendra [1 ]
机构：
[1] West Virginia Univ, Sch Med, Morgantown, WV 26506 USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1282
引用
收藏
页码：S971 / S971
页数：1
相关论文
共 50 条
  • [21] Glucagon-like Peptide-1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors
    Chiang, Cho-Han
    Song, Junmin
    Chi, Kuan-Yu
    Chang, Yu-Cheng
    Xanthavanij, Nutchapon
    Chang, Yu
    Hsia, Yuan Ping
    Chiang, Cho-Hung
    Ghamari, Azin
    Reynolds, Kerry L.
    Lin, Shuwen
    Xu, Xiaocao
    Neilan, Tomas G.
    EUROPEAN JOURNAL OF CANCER, 2025, 216
  • [22] Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns
    Lim, Soo
    Kim, Kyoung Min
    Nauck, Michael A.
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2018, 29 (04): : 238 - 248
  • [23] Reducing the Risks of Complex Pediatric Cardiovascular Surgery using Glucagon-Like Peptide 1 Peptides
    Lao, Robert
    Kobayashi, Yasuyuki
    Stanisic, Anamaria
    Hui, Wei
    Deng, Mimi
    Kadowaki, Sachiko
    Siraj, M. Ahsan
    Lamba, Manya
    Li, Jing
    Friedberg, Mark
    Husain, Mansoor
    Honjo, Osami
    CIRCULATION, 2024, 150
  • [24] Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study
    van Dalem, Judith
    Driessen, Johanna H. M.
    Burden, Andrea M.
    Stehouwer, Coen D. A.
    Klungel, Olaf H.
    de Vries, Frank
    Brouwers, Martijn C. G. J.
    HEPATOLOGY, 2021, 74 (05) : 2467 - 2477
  • [25] Cardiovascular events and all-cause mortality: effects of dual therapy intensification with insulin vs glucagon-like peptide-1 analogue
    Anyanwagu, U.
    Mamza, J.
    Mehta, R.
    Donnelly, R.
    Idris, I.
    Idris, I.
    DIABETOLOGIA, 2015, 58 : S452 - S452
  • [26] ACUTE PANCREATITIS RISK ASSOCIATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS USED FOR WEIGHT LOSS: A RETROSPECTIVE COHORT STUDY IN THE UNITED STATES
    Sarker, J.
    Lee, T. A.
    Winn, A. N.
    VALUE IN HEALTH, 2024, 27 (06) : S52 - S52
  • [27] Glucagon-Like Peptide-1 Receptor Agonists and Diabetic Cardiovascular Disease: Implications of the LEADER Study
    Swislocki, Arthur L. M.
    Jialal, Ishwarlal
    METABOLIC SYNDROME AND RELATED DISORDERS, 2016, 14 (08) : 375 - 377
  • [28] Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
    Sodhi, Mohit
    Rezaeianzadeh, Ramin
    Kezouh, Abbas
    Etminan, Mahyar
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (18): : 1795 - 1797
  • [29] Effects of glucagon-like peptide-1 receptor agonists on major coronary events in patients with type 2 diabetes
    Guo, Xueyuan
    Sang, Caihua
    Tang, Ribo
    Jiang, Chenxi
    Li, Songnan
    Liu, Nian
    Long, Deyong
    Du, Xin
    Dong, Jianzeng
    Ma, Changsheng
    DIABETES OBESITY & METABOLISM, 2023, 25 : 53 - 63
  • [30] Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study
    Pasternak, Bjorn
    Wintzell, Viktor
    Eliasson, Bjorn
    Svensson, Ann-Marie
    Franzen, Stefan
    Gudbjornsdottir, Soffia
    Hveem, Kristian
    Jonasson, Christian
    Melbye, Mads
    Svanstrom, Henrik
    Ueda, Peter
    DIABETES CARE, 2020, 43 (06) : 1326 - 1335
12345